Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rimegepant
- Development stage
- Approved
- Lead developer
- Biohaven
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Rimegepant is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist used for both the acute treatment of migraine with or without aura and the preventive treatment of episodic migraine in adults. It works by binding with high affinity to the human CGRP receptor, thereby blocking CGRP activity and preventing vasodilation and decreased excitability of Aδ nerves associated with migraine pathophysiology. Unlike triptans, it does not cause vasoconstriction, making it suitable for patients with cardiovascular contraindications to triptans. Rimegepant was originally developed by Biohaven Pharmaceuticals and is marketed under the brand names Nurtec ODT (United States) and Vydura (European Union)[1][3][5][7][8].
- Brand names
- Nurtec ODTVydura
- Other names
- N-TEC
02
Targets
AMY (Pancreatic alpha-amylase)Calcitonin gene-related peptide type 1 receptor
Beyond the preview
Go deeper on rimegepant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rimegepant.